{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:25:22Z","timestamp":1788967522430,"version":"build-2803163510"},"reference-count":137,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.numecd.2023.07.019","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T02:58:09Z","timestamp":1689735489000},"page":"1866-1877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA)"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1210","authenticated-orcid":false,"given":"Giulia","family":"Chiesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-3990","authenticated-orcid":false,"given":"Maria Grazia","family":"Zenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-1999","authenticated-orcid":false,"given":"Andrea","family":"Baragetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-038X","authenticated-orcid":false,"given":"Carlo M.","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-2234","authenticated-orcid":false,"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-2829","authenticated-orcid":false,"given":"Davide","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-9780","authenticated-orcid":false,"given":"Angela A.","family":"Rivellese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Sampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-0373","authenticated-orcid":false,"given":"Francesco","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2023.07.019_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI113849","article-title":"Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis","volume":"83","author":"Kraft","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2023.07.019_bib2","doi-asserted-by":"crossref","first-page":"24004","DOI":"10.1074\/jbc.270.41.24004","article-title":"The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a)","volume":"270","author":"Lawn","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2023.07.019_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF00282175","article-title":"The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen","volume":"79","author":"Frank","year":"1988","journal-title":"Hum Genet"},{"key":"10.1016\/j.numecd.2023.07.019_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2023.07.019_bib5","doi-asserted-by":"crossref","first-page":"15471","DOI":"10.1074\/jbc.270.26.15471","article-title":"A two-step model for lipoprotein(a) formation","volume":"270","author":"Trieu","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2023.07.019_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0005-2760(79)90131-0","article-title":"Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B","volume":"575","author":"Krempler","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.numecd.2023.07.019_bib7","doi-asserted-by":"crossref","first-page":"24369","DOI":"10.1016\/S0021-9258(18)35775-2","article-title":"Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a)","volume":"267","author":"Chiesa","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2023.07.019_bib8","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0022-2275(20)39785-6","article-title":"Apolipoprotein[a] is not associated with apolipoprotein B in human liver","volume":"35","author":"Wilkinson","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2012.09.031","article-title":"In\u00a0vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)","volume":"225","author":"Frischmann","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0021-9150(00)00732-2","article-title":"The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans","volume":"157","author":"Demant","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib12","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2023.07.019_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","article-title":"Recent advances in demystifying the metabolism of lipoprotein(a)","volume":"349","author":"Chemello","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib16","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/01.STR.26.9.1582","article-title":"Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study","volume":"26","author":"Willeit","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.numecd.2023.07.019_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.08.018","article-title":"Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study","volume":"37","author":"Fogacci","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib18","first-page":"205","article-title":"Lipoprotein(A) levels and apoprotein(a) phenotypes in a Sicilian population","volume":"13","author":"Noto","year":"1998","journal-title":"Ann Ital Med Int"},{"key":"10.1016\/j.numecd.2023.07.019_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abg8289","article-title":"Protein-coding repeat polymorphisms strongly shape diverse human phenotypes","volume":"373","author":"Mukamel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.numecd.2023.07.019_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0009-8981(02)00390-X","article-title":"Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability","volume":"328","author":"Noto","year":"2003","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.numecd.2023.07.019_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014581","article-title":"Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans","volume":"6","author":"Deo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2023.07.019_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.07.019_bib24","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1172\/JCI117263","article-title":"Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common \"null\" allele at the apo(a) locus","volume":"93","author":"Gaw","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2023.07.019_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0021-9150(97)06105-4","article-title":"Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a)","volume":"131","author":"Ritter","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/nu12072024","article-title":"Diet and lp(a): does dietary change modify residual cardiovascular risk conferred by lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.numecd.2023.07.019_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pathol.2018.09.062","article-title":"Nonfasting versus fasting lipid profile for cardiovascular risk prediction","volume":"51","author":"Langsted","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.numecd.2023.07.019_bib29","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"Muller","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib30","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1046\/j.1523-1755.1999.00489.x","article-title":"Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome","volume":"55","author":"Noto","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.numecd.2023.07.019_bib31","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2023.07.019_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/qjmed\/93.2.75","article-title":"Lipoprotein(a): from ancestral benefit to modern pathogen?","volume":"93","author":"Lippi","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.numecd.2023.07.019_bib33","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.numecd.2023.07.019_bib34","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"Hancock","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2023.07.019_bib35","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib36","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib37","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib40","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"322","author":"Seed","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib41","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease. A study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.numecd.2023.07.019_bib42","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI115645","article-title":"Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease","volume":"89","author":"Sandholzer","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2023.07.019_bib43","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib44","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) may Be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.07.019_bib46","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.07.019_bib47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.numecd.2023.07.019_bib48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.07.019_bib49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib50","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered\u00a0human\u00a0lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib51","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal effect of lp(a) [Lipoprotein(a)] level on ischemic stroke and alzheimer disease: a mendelian randomization study","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.numecd.2023.07.019_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib54","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib55","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2014.13959","article-title":"Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis","volume":"312","author":"Smith","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2023.07.019_bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.numecd.2023.07.019_bib57","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.1993.03510180065035","article-title":"A prospective study of lipoprotein(a) and the risk of myocardial infarction","volume":"270","author":"Ridker","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2023.07.019_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0021-9150(94)90078-7","article-title":"Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study","volume":"106","author":"Alfthan","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.07.019_bib60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2023.07.019_bib61","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2023.07.019_bib62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib63","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2023.07.019_bib64","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.07.019_bib65","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.07.019_bib66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib67","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.12056","article-title":"Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women","volume":"11","author":"Danik","year":"2013","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.numecd.2023.07.019_bib68","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib69","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/01.CIR.91.4.948","article-title":"Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a)","volume":"91","author":"Terres","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.07.019_bib70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/hrt.74.4.365","article-title":"Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction","volume":"74","author":"Tamura","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.01.020","article-title":"Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease","volume":"246","author":"Niccoli","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib72","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0002-9149(94)90279-8","article-title":"Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group","volume":"73","author":"Daida","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib74","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.07.019_bib75","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib76","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib77","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglyceride and impact on global health outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib78","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.07.019_bib79","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2023.07.019_bib80","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib81","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib82","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2023.07.019_bib83","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","article-title":"Lipoprotein (a) and diabetes mellitus","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib85","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2337\/dc19-1398","article-title":"The association of lipoprotein(a) plasma levels with prevalence of cardiovascular disease and metabolic control status in patients with type 1 diabetes","volume":"43","author":"Littmann","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.019_bib86","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.numecd.2018.05.010","article-title":"Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus","volume":"28","author":"Zhang","year":"2018","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2023.07.019_bib87","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","article-title":"Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the Atherosclerosis Risk in Communities study","volume":"282","author":"Saeed","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib89","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2023.07.019_bib90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2023.07.019_bib91","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12944-021-01504-x","article-title":"High lipoprotein(a) concentrations are associated with lower type 2 diabetes risk in the Chinese Han population: a large retrospective cohort study","volume":"20","author":"Fu","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2023.07.019_bib92","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.ATV.18.8.1335","article-title":"Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype","volume":"18","author":"Rainwater","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.07.019_bib93","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1194\/jlr.P049015","article-title":"Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population","volume":"56","author":"Ding","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib94","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s001250051110","article-title":"Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes","volume":"42","author":"Neele","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2023.07.019_bib95","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib96","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacl.2019.01.010","article-title":"LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia","volume":"13","author":"Bogsrud","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2023.07.019_bib97","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish familial hypercholesterolemia cohort study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.07.019_bib98","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/eurjpc\/zwab185","article-title":"A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort","volume":"29","author":"Perez de Isla","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib99","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2022.02.016","article-title":"Plasma Lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period","volume":"349","author":"Wodaje","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2022.01.022","article-title":"Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis","volume":"349","author":"Bhatia","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib101","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacl.2017.01.002","article-title":"Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia","volume":"11","author":"Lazaro","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2023.07.019_bib102","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib103","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2023.07.019_bib104","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Marcovina","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib106","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2023.07.019_bib107","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2023.07.019_bib108","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 Years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.07.019_bib109","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.transci.2018.07.015","article-title":"Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study","volume":"57","author":"Bigazzi","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.numecd.2023.07.019_bib110","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib111","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Group","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib112","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.numecd.2023.07.019_bib113","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5603\/KP.a2019.0013","article-title":"Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials","volume":"77","author":"Wang","year":"2019","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.numecd.2023.07.019_bib114","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy\u00a0increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib115","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1093\/eurheartj\/ehy311","article-title":"PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?","volume":"39","author":"Pirillo","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib116","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib117","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","article-title":"Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.numecd.2023.07.019_bib118","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2023.07.019_bib120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib121","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2023.07.019_bib122","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib123","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2023.07.019_bib124","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events and lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O'Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib125","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2023.07.019_bib126","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2023.07.019_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \"Lp(a) clinic\": a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib128","first-page":"1129","article-title":"Canadian cardiovascular society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100343","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)","volume":"10","author":"Chakraborty","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2021.11.004","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a)","volume":"349","author":"Chakraborty","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.07.019_bib131","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1542\/peds.89.3.401","article-title":"Early expression of the apolipoprotein (a) gene: relationships between infants' and their parents' serum apolipoprotein (a) levels","volume":"89","author":"Wang","year":"1992","journal-title":"Pediatrics"},{"key":"10.1016\/j.numecd.2023.07.019_bib132","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jacl.2018.07.014","article-title":"In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members","volume":"12","author":"Zawacki","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2023.07.019_bib133","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1177\/2047487319888059","article-title":"A large Italian cohort on proprotein convertase subtilisin\/kexin type 9 inhibitors","volume":"27","author":"Sbrana","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2023.07.019_bib134","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2023.07.019_bib135","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jacl.2015.07.006","article-title":"Lipoprotein(a): its relevance to the pediatric population","volume":"9","author":"McNeal","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2023.07.019_bib136","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/STROKEAHA.118.024692","article-title":"Multilevel models to estimate carotid intima-media thickness curves for individual cardiovascular risk evaluation","volume":"50","author":"Olmastroni","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.numecd.2023.07.019_bib137","first-page":"267","article-title":"Distribution of risk factors, plasma lipids, lipoproteins and dyslipidemias in a small Mediterranean island: the Ustica Project","volume":"12","author":"Barbagallo","year":"2002","journal-title":"Nutr Metabol Cardiovasc Dis"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323002880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323002880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:26:22Z","timestamp":1760545582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475323002880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":137,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0939475323002880"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2023.07.019","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA)","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2023.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}]}}